ANIP ANI PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1023024 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY25.9%
TTM net income YoY188.0%
TTM EPS YoY214.4%
Revenue 3-yr CAGR32.3%
Net income 3-yr CAGR105.9%
Margins
Gross margin61.1%
Operating margin16.0%
Net margin11.2%
FCF margin19.7%
EBITDA margin23.9%
Returns
ROE20.4%
ROA7.9%
ROIC (approx.)23.0%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets59.4%
Debt / equity0.47x
Current ratio2.75x
Interest coverage5.44x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-7.6%
Payout ratio0.0%
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $883.37M | $614.38M |
| Cost of revenue | $341.31M | $250.21M |
| Gross profit | $542.06M | $364.17M |
| R&D expense | $51.66M | $44.58M |
| SG&A expense | $317.75M | $249.64M |
| Operating income | $111.09M | $584,000 |
| Interest expense | $32.56M | $33.63M |
| Pretax income | $95.79M | -$22.21M |
| Income tax | $17.45M | -$3.69M |
| Net income | $78.34M | -$18.52M |
| EBITDA | $202.51M | $68.31M |
| EPS (basic) | 3.50 | -1.04 |
| EPS (diluted) | 3.32 | -1.04 |
| Weighted avg. shares (diluted) | 21.23M | 19.32M |
| Balance sheet | ||
| Cash & equivalents | $285.58M | $144.86M |
| Receivables | $281.08M | $221.73M |
| Inventory | $143.07M | $136.78M |
| Current assets | $753.12M | $528.46M |
| PP&E, net | $62.48M | $56.86M |
| Goodwill | $62.48M | $59.99M |
| Intangibles | $479.53M | $541.83M |
| Total assets | $1.44B | $1.28B |
| Current liabilities | $278.11M | $194.45M |
| Short-term debt | $17.27M | $9.17M |
| Long-term debt | $291.84M | $309.11M |
| Total debt | $309.11M | $318.28M |
| Total liabilities | $899.65M | $855.94M |
| Shareholders' equity | $540.72M | $403.68M |
| Net debt | $23.52M | $173.42M |
| Shares outstanding | 22.49M | 21.11M |
| Cash flow statement | ||
| Operating cash flow | $185.22M | $64.02M |
| Capital expenditure | $13.84M | $16.24M |
| Free cash flow | $171.39M | $47.78M |
| Investing cash flow | -$34.32M | -$404.72M |
| Financing cash flow | -$9.94M | $264.94M |
| Depreciation & amortization | $91.42M | $67.73M |
| Stock-based compensation | $37.93M | $29.34M |
| Dividends paid | $1.16M | $1.62M |
| Share buybacks | $12.21M | $10.96M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.